Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 4/20 | 0.48 |
| ▸ | THRB | P10828 | 4/20 | 0.48 |
| ▸ | ESR1 | P03372 | 4/20 | 0.43 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.43 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25330542 | 0.93 | ESR1 (0.41) | THRATHRBESR1NR5A1S1PR2 | |
| SCHEMBL25328681 | 0.87 | PTGS1 (0.38) | THRATHRBESR1 | |
| SCHEMBL27524926 | 0.82 | THRA (0.45) | THRATHRBESR1NR5A1S1PR2 | |
| SCHEMBL5589792 | 0.81 | ESR1 (0.46) | THRATHRBESR1NR5A1AKR1C4 | |
| SCHEMBL1375338 | 0.81 | ESR1 (0.48) | ESR1NR5A1AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL25328991 | 0.80 | ALDH1A1 (0.45) | THRBESR1 | |
| SCHEMBL25328769 | 0.78 | ESR1 (0.38) | THRATHRBESR1NR5A1S1PR2 | |
| SCHEMBL688956 | 0.78 | ESR1 (0.49) | THRBESR1NR5A1AKR1C4AKR1C3 | |
| Iodide SCHEMBL10381593 | 0.78 | THRA (0.43) | THRATHRBESR1S1PR2S1PR1 | |
| SCHEMBL25329050 | 0.78 | NPSR1 (0.41) | THRATHRBESR1NR5A1S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002533379-A | — | — | 2002-10-08 | — | — | JP | claimed |
| EP-1140021-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG (DE) | 2001-10-10 | — | — | EP | claimed |
| WO-2000038653-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG. (DE) | 2000-07-06 | — | — | WO | claimed |
| US-11547665-B2 | Multiphasic compositions | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2023-01-10 | — | — | US | disclosed |
| US-20220370353-A9 | BLENDED FORMULATIONS | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2022-11-24 | — | — | US | disclosed |
| US-20140017302-A1 | OPTIMISED PREPARATIONS OF HIGHLY ADAPTABLE AGGREGATES | CEVC GREGOR (DE) | 2014-01-16 | — | — | US | disclosed |
| EP-1140021-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG (DE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000038653-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG. (DE) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140017302-A1 | OPTIMISED PREPARATIONS OF HIGHLY ADAPTABLE AGGREGATES | CD68, CHMP4B, ANXA5 | THRA 4282/4885THRB 4529/4885ESR1 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.